Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

Business Leaders

HomeAll NewsMost read newsBusiness Leaders Biography 
Portrait de Robert Davis
Age : 71
Public asset : 928,168 USD
Country of residence : Unknown
Linked companies : Intra-Cellular Therapies, Inc.

Summary 
Currently, Robert E. Davis holds the position of Chief Scientific Officer & Senior Vice President at Intra-Cellular Therapies, Inc.

Dr. Davis previously held the position of President & Chief Executive Officer for 3D Pharmaceutical Consultants, Inc., Executive Vice President of ACADIA Pharmaceuticals, Inc. and President, Chief Executive & Scientific Officer at MitoKor, Inc.

Dr. Davis received an undergraduate degree, a doctorate and a graduate degree from the University of Illinois.




Current positions of Robert Davis 
Robert Davis : Personal Network 
Most Read News 
01/25Musk says China rivals 'work hardest, smartest'
RE
01/26LVMH's Arnault brushes off succession question
RE
01/27Wood's ARK Innovation Fund on pace for best month ever as battered stocks surge
RE
01/19Ark's Wood remains bullish on Tesla, says oil stock rally 'defying logic'
RE
01/26Bill Ackman says Hindenburg's report on Adani Group 'highly credible'
RE
01/19JPMorgan CEO Dimon sees interest rates going beyond 5% - CNBC
RE
01/23Musk to return to stand in fraud trial over 2018 Tesla tweet
RE
01/19Sacked GM workers in India sue company, CEO Barra for unpaid compensation
RE
01/20Musk expected to take stand as trial resumes over Tesla tweet
RE
01/26Wells Fargo CEO Scharf's 2022 pay unchanged at $24.5 million
RE
More news


© 2023 People and Ownership :   
Robert Davis : Connections 


Latest news about Robert Davis 
01/09Transcript : Merck & Co., Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 05:15 PM
CI
01/05Transcript : Merck & Co., Inc. Presents at Goldman Sachs Annual Healthcare CEOs Unscripted Conference, Jan-05-2023 08:55 AM
CI
2022Trending : Merck to Acquire Imago BioSciences for $1.35 Billion
DJ
2022Merck Eyes Expanded Blood Disorder Drug Pipeline Via $1.35 Billion Buyout of Imago BioSciences
MT
2022Insider Sell: Doubleverify Holdings
MT
2022Trending : Merck Raises Outlook After 3Q Beats Expectations
DJ
2022Transcript : Merck & Co., Inc., Q3 2022 Earnings Call, Oct 27, 2022
CI
More news